Axsome Therapeutics price target raised to $200 from $185 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $185 and keeps a Buy rating on the shares after the AXS-05 regulatory application was accepted with priority review. The firm increased its market penetration assumptions for AXS-05 given the potential for regulatory approval and market entry during the first half of 2026.